

1 **BNT162b2 induced neutralizing and non-neutralizing antibody functions against**
2 **SARSCoV-2 diminish with age**

3

4 Timothy A. Bates^{#1}, Pei Lu^{#2}, Ye jin Kang², Devin Schoen³, Micah Thornton⁴, Savannah K.

5 McBride¹, Chanhee Park⁴, Daehwan Kim⁴, William B. Messer¹, Marcel E. Curlin^{*3}, Fikadu G.

6 Tafesse^{*1}, Lenette L. Lu^{*2, 5, 6}

7

8 1. Department of Molecular Microbiology and Immunology, Oregon Health and Sciences

9 University, Portland, OR

10 2. Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine,

11 UT Southwestern Medical Center, Dallas, TX

12 3. Department of Occupational Health, Oregon Health and Sciences University, Portland, OR

13 4. Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX

14 5. Department of Immunology, UT Southwestern Medical Center, Dallas, TX

15 6. Parkland Health & Hospital System

16 # These authors contributed equally.

17

18 *Correspondence:

19 Lenette Lu MD PhD

20 Lenette.Lu@UTSouthwestern.edu

21 UT Southwestern Medical Center

22 5323 Harry Hines Blvd, Dallas, TX 75390

23 214-645-1486

24

25 Fikadu G. Tafesse PhD – tafesse@ohsu.edu

26 Marcel E Curlin MD – curlin@ohsu.edu

27 **Abstract**

28 Each novel SARS-CoV-2 variant renews concerns about decreased vaccine efficacy caused by
29 evasion of vaccine induced neutralizing antibodies. However, accumulating epidemiological
30 data show that while vaccine prevention of infection varies, protection from severe disease and
31 death remains high. Thus, immune responses beyond neutralization could contribute to vaccine
32 efficacy. Polyclonal antibodies function through their Fab domains that neutralize virus directly,
33 and Fc domains that induce non-neutralizing host responses via engagement of Fc receptors on
34 immune cells. To understand how vaccine induced neutralizing and non-neutralizing activities
35 synergize to promote protection, we leverage sera from 51 SARS-CoV-2 uninfected health-care
36 workers after two doses of the BNT162b2 mRNA vaccine. We show that BNT162b2 elicits
37 antibodies that neutralize clinical isolates of wildtype and five variants of SARS-CoV-2, including
38 Omicron BA.2, and, critically, induce Fc effector functions. FcγRIIIa/CD16 activity is linked to
39 neutralizing activity and associated with post-translational afucosylation and sialylation of
40 vaccine specific antibodies. Further, neutralizing and non-neutralizing functions diminish with
41 age, with limited polyfunctional breadth, magnitude and coordination observed in those ≥65
42 years old compared to <65. Thus, studying Fc functions in addition to Fab mediated
43 neutralization provides greater insight into vaccine efficacy for vulnerable populations such as
44 the elderly against SARS-CoV-2 and novel variants.

45

46 **Introduction**

47 Neutralizing antibody responses are among the core measures of vaccine efficacy in the
48 COVID-19 pandemic (Garcia-Beltran et al., 2022; Liu et al., 2021). Yet even when neutralization
49 is compromised in the setting of new SARS-CoV-2 variants (Planas et al., 2022) and cases of
50 vaccine breakthrough infections rise, protection from hospitalization remains relatively high
51 (Altarawneh et al., 2022; Collie et al., 2022; Nasreen et al., 2022; Tang et al., 2021). Thus, the

52 continued emergence of new variants highlights the need to understand vaccine efficacy
53 through protection from disease in addition to prevention of infection.

54
55 Though one of the key components of immune protection, the complexity of polyclonal antibody
56 responses and its roles in disease remain only partially understood. For SARS-CoV-2, attention
57 has focused on leveraging direct neutralization of virus by antigen recognition via the Fab
58 domain. However, the overall magnitude of neutralizing responses in patients with severe
59 COVID-19 is higher compared to mild disease, suggesting that neutralizing activity alone poorly
60 captures the capacity to protect from serious illness (Lucas et al., 2021; Savage et al., 2021).

61 Independently, data from multiple large clinical trials have demonstrated that convalescent
62 plasma carrying neutralizing activity does not prevent infection or disease in humans (Begin et
63 al., 2021; Group, 2021; Writing Committee for the et al., 2021), suggesting that passive transfer
64 of neutralizing polyclonal antibodies is insufficient to confer protection. These lines of evidence
65 show that in SARS-CoV-2 infection, more nuanced evaluations of neutralizing responses with
66 respect to potency (Garcia-Beltran et al., 2021) and dynamics (Lucas et al., 2021), and immune
67 responses beyond neutralization are vital in understanding pathogenesis.

68
69 Antibodies function through the combination of the Fab domain that directs neutralizing activity
70 against microbial targets and the Fc domain that induces non-neutralizing functions (Lu et al.,
71 2018). Through binding Fc receptors expressed on innate and adaptive immune cells as well as
72 activation of complement, antibody Fc domains have the ability to induce a spectrum of host
73 responses directed against an antigen recognized by the Fab domain (Pincetic et al., 2014).
74 Thus, antibody Fc effector functions have the potential to impact outcomes of SARS-CoV-2
75 infection and protection in vaccines.

76

77 Studies using monoclonal antibodies targeting SARS-CoV-2 show that Fc effector functions can
78 be protective. Passive transfer of monoclonal antibodies with mutations that abrogate Fc
79 domain binding to Fc receptors result in increased SARS-CoV-2 viral load and decreased
80 survival in multiple animal models when compared to intact antibodies (Schafer et al., 2021;
81 Suryadevara et al., 2021; Ullah et al., 2021; Yamin et al., 2021). This effect is more pronounced
82 with therapeutic than prophylactic administration (Winkler et al., 2021). Thus, monoclonal
83 antibody Fc functions support neutralizing activity to prevent viral entry. Moreover, even after
84 viral infection, Fc functions can inhibit disease progression.

85
86 Conversely, several lines of evidence show that Fc effector functions in polyclonal responses
87 during SARS-CoV-2 infection could be pathogenic. Post-translational IgG glycosylation is
88 altered with disease severity in many ways (Farkash et al., 2021; Petrovic et al., 2021; Vicente
89 et al., 2022) but one consistent observation across several studies is that decreased IgG
90 fucosylation correlates with worsening clinical symptoms and hospitalization (Chakraborty et al.,
91 2021; Chakraborty et al., 2022; Larsen et al., 2021). The proposed mechanism of pathology is
92 through increased binding to the activating Fc receptor FcγRIIIa/CD16a. In an *in vitro* poly I:C
93 stimulated human macrophage model with FcγRIIIa/CD16a expression, addition of afucosylated
94 compared to fucosylated IgG from patients infected with SARS-CoV-2 enhances secretion of
95 the pro-inflammatory cytokine IL-6 (Hoepel et al., 2021; Larsen et al., 2021). In monocytes,
96 FcγR mediated activation can cause pyroptosis (Junqueira et al., 2022). In a human Fc receptor
97 transgenic mouse model, passive transfer of afucosylated polyclonal IgG from individuals with
98 severe COVID-19 increases production of IL-6 and TNF α but not the anti-inflammatory IL-10
99 (Chakraborty et al., 2022). Consistent with these data, FcγRIIIa/CD16a natural killer (NK) cell
100 activation that leads to antibody dependent cellular cytotoxicity (ADCC) is enhanced with
101 symptom severity and normalizes upon convalescence (Chakraborty et al., 2021). The low

102 affinity activating Fc γ RIIa/CD32a and inhibitory Fc γ RIIb/CD32b along with the high affinity
103 Fc γ RI/CD64 mediate the non-neutralizing Fc effector functions of antibody dependent cellular
104 phagocytosis (ADCP) by monocytes. Neutrophils express antibody receptors for both IgG, the
105 activating high affinity Fc γ RI, low affinity Fc γ RIIa and Fc γ RIIIB, as well as IgA, the low affinity
106 Fc α RI. These, along with complement receptors CR1 and CR3 contribute to neutrophil
107 phagocytosis. Finally, C1q binding to IgG and IgM Fc domains activate complement pathways
108 through C3 deposition (Lofano et al., 2018; Peschke et al., 2017; Quast et al., 2015; van Osch
109 et al., 2021). In contrast to Fc γ RIIIa/CD16a activities, the implications of Fc γ RIIa/CD32a and
110 Fc γ RIIb/CD32b mediated phagocytosis and complement activation in SARS-CoV-2 are less
111 clear given the variability in cohort populations with respect to clinical outcomes, demographics
112 and co-morbidities (Adeniji et al., 2021; Bartsch et al., 2021; Herman et al., 2021; Klingler et al.,
113 2021; Selva et al., 2021). However, that multiple Fc effector functions in infection and disease
114 are detectable suggest that these responses if induced by vaccines could influence outcomes.
115
116 For COVID-19 vaccines, neutralizing titers are often used to extrapolate protective efficacy
117 (Lustig et al., 2021). While antibody dependent NK cell activation (ADNKA), ADCC, ADCP by
118 monocytes, ADNP by neutrophils and complement activation are also elicited (Alter et al., 2021;
119 Gorman et al., 2021; Kaplonek et al., 2022), it is unclear whether these Fc effector functions are
120 protective, inert, or pathogenic. Moreover, how non-neutralizing antibody functions impact direct
121 neutralization of live virus is not known. To assess the relationships between Fab and Fc
122 domain functions in polyclonal responses from vaccination, we evaluated immune sera from
123 SARS-CoV-2 uninfected health-care workers who received two doses of the BNT162b2 mRNA
124 vaccine. We assessed neutralization against SARS-CoV-2 wildtype virus (WA.1) and five
125 clinical variants: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron
126 (BA.2). We measured vaccine specific antibody Fc features of isotype, Fc receptor binding, Fc

127 effector functions and IgG glycosylation. We found heterogeneous neutralizing and non-
128 neutralizing antibody responses. Neutralization across variants correlated with FcγRIIIa/CD16a
129 effector functions in an age but not sex dependent manner. Post-translational afucosylation and
130 sialylation of vaccine specific antibodies associated with enhanced FcγRIIIa/CD16a activity.
131 Neutralizing and non-neutralizing functions independently and collectively diminished with age,
132 limiting polyfunctional breadth, magnitude, and coordination in those ≥65 years old compared to
133 <65. Our results show that assessment of vaccine efficacy against SARS-CoV-2 and novel
134 variants is enhanced by the addition of diverse Fc functions to traditional Fab functions,
135 particularly in vulnerable populations such as the elderly.

136

137 **Results**

138 Study subjects

139 To evaluate polyclonal antibody responses to mRNA COVID-19 vaccines, sera were collected
140 from 51 adults who received two doses of BNT162b2 vaccine between December 2020 and
141 February 2021 (Table) (Bates et al., 2021a). These individuals spanned a spectrum of ages
142 from 21-82 years. To limit confounding variables, samples were selected to minimize variations
143 in time between vaccine dose 1 and 2 (20-22 days, variation of 2 days) and dose 2 to sample
144 collection (14-15 days, variation of 1 day); sex distribution was balanced. To avoid the
145 complicating factor of hybrid immunity due to SARS-CoV-2 infection, we excluded individuals
146 with report of prior infection or active symptoms and performed confirmatory testing to verify the
147 absence of detectable SARS-CoV-2 nucleocapsid specific antibodies (Supplemental Figure 1A).

148

149 Neutralizing antibody titers of wildtype and SARS-CoV-2 variants

150 Using the SARS-CoV-2 receptor binding domain (RBD) antigen encoded by BNT162b2 (Vogel
151 et al., 2021), we found that 100% of individuals after two doses of the vaccine had detectable
152 antigen specific IgG compared to 51% with IgA (Supplemental Figure 1A). Thus, consistent with

153 other studies, the primary isotype mediating antibody function two weeks after a second
154 BNT162b2 dose was IgG (Brewer et al., 2022; Collier et al., 2021). To assess direct
155 neutralization, we performed focus reduction neutralization tests using live wildtype SARS-CoV-
156 2 (isolate WA1/2020) virus (Supplemental Figure 1B). Consistent with the generation of RBD
157 specific IgG, all individuals had detectable capacity to neutralizing activity. Linear regression
158 showed that neutralization was dependent on RBD specific antibodies, specifically IgG and not
159 IgA (Figure 1A).

160
161 We next measured the neutralizing activity of vaccinee sera against SARS-CoV-2 clinical
162 isolates of the viral variants Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2)
163 and Omicron (BA.2), (Wang et al., 2022) (Supplemental Figure 1B). We used live virus instead
164 of pseudovirus to more effectively model physiological ratios and spectrum of SARs-CoV-2
165 antigens during infection and replication (Syed et al., 2021). We found that neutralization of
166 variants was diminished relative to wildtype and varied by viral variant and individual (Figure 1B)
167 with the lowest levels detected against Omicron (BA.2), consistent with other studies (Evans et
168 al., 2022; Kurhade et al., 2022; Wang et al., 2022). More specifically, while all individuals had
169 detectable neutralization against wildtype and Alpha (B.1.1.7), only 57% had detectable
170 responses against Omicron (BA.2) which were lower on average than for other variants. While
171 sex can impact immune responses (Scully et al., 2020), we observed no sex based difference in
172 neutralization. (Supplemental Figure 1C). However, we did detect a negative correlation
173 between age and neutralization (Supplemental Figure 1D). To incorporate both age and sex into
174 our evaluations, we used multivariable regression to assess the relationships with neutralization.
175 We found that neutralization of wildtype and variants was negatively correlated with age (Figure
176 1C-H) but the correlation with sex remained non-significant. Upon review of the 43% of
177 individuals with no detectable neutralizing activity against Omicron (BA.2), we observed that the
178 median age of this subgroup was 63.5 years, above the median age of 50 for all individuals in

179 this study. Consistent with other reports, these data showed that BNT162b2 induced RBD IgG
180 neutralized SARS-CoV-2 wildtype virus and multiple variants in an age but not sex dependent
181 manner (Bates et al., 2021a; Collier et al., 2021; Kawasuji et al., 2021).

182

183 Vaccine specific Fc effector functions

184 Because IgG was the predominant vaccine specific isotype, we focused on RBD specific IgG
185 effector functions to evaluate the relationship between viral neutralization via by the Fab domain
186 and non-neutralizing Fc activity. We began by measuring RBD specific antibody binding to the
187 activating receptors, FcγRIIIa/CD16a and FcγRIIa/CD32a, and the sole inhibitory receptor,
188 FcγRIIb/CD32b, because engagement of these low affinity Fc receptors are modifiable by
189 dynamic changes in subclass and post-translational glycosylation (Alter et al., 2018;
190 Nimmerjahn and Ravetch, 2005; Pincetic et al., 2014). We found that RBD specific IgG binding
191 to FcγRIIIa/CD16a (Figure 2A), FcγRIIa/CD32a (Figure 2B) and FcγRIIb/CD32b (Figure 2C)
192 positively correlated with SARS-CoV-2 neutralization in varying degrees.

193

194 Because Fc domain engagement is only the first step in signaling and initiation of effector
195 functions, we examined the downstream consequences of activation by measuring RBD antibody
196 dependent natural killer cell activation (ADNKA) which leads to antibody dependent cellular
197 cytotoxicity (ADCC) (Chung et al., 2015), antibody dependent cellular and neutrophil phagocytosis
198 (ADCP and ADNP) and antibody dependent complement deposition (ADCD). We found that
199 neutralization titers positively correlated with all three markers of ADNKA: CD107a degranulation
200 and intracellular IFNγ and TNFα production (Figure 2D-F). This association was not observed
201 with ADNP (Figure 2G) and ADCP (Supplemental Figure 2A) and was less statistically significant
202 with C3 deposition in ADCD (Supplemental Figure 2A). Because the primary Fc receptor that
203 induces ADNKA is FcγRIIIa/CD16a, these findings corroborated data with respect to binding
204 (Figure 2A). In contrast, the combinatorial engagement of low and high affinity FcγRs and the

205 Fc α R on neutrophils in ADNP did not correlate with neutralization (Figure 2G). Along these lines,
206 the ratio of activating Fc γ RIIa/CD32a and, to a lesser degree, Fc γ RIIIa/CD16a, to the inhibitory
207 Fc γ RIIb/CD32b involved in ADCP in THP-1 monocytes did not relate to neutralization
208 (Supplemental Figure 2A and Figure 2H). The link between Fc γ RIIIa/CD16a NK cell activation
209 and neutralization was sustained across variants, though fits again varied (Figure 2H and
210 Supplemental Figure 2B). These data together demonstrated that in contrast to Fc γ RIIa/CD32a
211 and Fc γ RIIb/CD32b, vaccine specific IgG induction of Fc γ RIIIa/CD16a functions associated with
212 neutralization.

213

214 IgG glycosylation

215 As in many infectious and non-infectious processes, post-translational glycosylation of polyclonal
216 IgG has been shown to mediate binding affinity to Fc receptors in SARS-CoV-2 infection
217 (Chakraborty et al., 2021; Chakraborty et al., 2022; Hoepel et al., 2021; Larsen et al., 2021). A
218 core biantennary structure on the conserved asparagine residue N297 on the Fc domain is
219 modified by the addition and subtraction of galactose (G), sialic acid (S), fucose (F) and bisecting
220 N-acetylglucosamine (GlcNAc) to generate glycoform diversity (Arnold et al., 2007)
221 (Supplemental Figure 3A). Monoclonal and polyclonal antibody studies have shown that changes
222 in glycoform composition have the potential to impact binding and downstream effector functions
223 (Supplemental Figure 3A) (Alter et al., 2018; Arnold et al., 2007; Peschke et al., 2017; Quast et
224 al., 2015; van Osch et al., 2021). To evaluate the impact of glycosylation on vaccine induced
225 antibodies, we measured the relative abundance of N-glycans on total non-antigen and RBD
226 specific IgG (Supplemental Figure 3B). For each individual, non-antigen compared to RBD
227 specific IgG glycoforms were distinct (Figure 3A and 3B). Glycoforms (Supplemental Figure 3C)
228 containing fucose (Figure 3C), total sialic (Figure 3D) composed of di-sialic (Figure 3E) and mono-
229 sialic (Figure 3F) acids, galactose (di-galactosylated in Figure 3G and agalactosylated and mono-

230 galactosylated in Supplemental Figure 3D) and bisecting GlcNAc (Supplemental Figure 3E) were
231 significantly different between total non-antigen and RBD specific IgG.

232
233 To evaluate if differential antibody glycosylation impacted effector functions associated with
234 neutralization, we investigated which glycoforms lead to FcγRIIIa/CD16a mediated NK cell
235 activation by linear regression. We found that relative levels of RBD and not total non-antigen
236 specific IgG glycoforms significantly correlated with CD107a degranulation, intracellular IFN γ and
237 TNF α production at varying levels (Supplemental Figure 4A-D). Relative levels of IgG glycoforms
238 that contained fucose without sialic acid (asialylated fucosylated) and glycoforms that contained
239 sialic acid (specifically di-sialic and not mono-sialic acid) correlated with all three markers of NK
240 cell activation (Figure 3H-K). The negative relationship between asialylated fucosylated species
241 on RBD specific IgG with ADNKA indicated an inhibitory effect of the presence of fucose. This
242 contrasted with sialic acid, where the absence negatively (Figure 3H and Supplemental Figure
243 4E and H) and presence positively (Figure 3I and J and Supplemental Figure 4 F-G, I-J)
244 associated with ADNKA. Taken together, these data showed that fucose and sialic acid on
245 vaccine specific IgG influence FcγRIIIa/CD16a NK cell activation in opposing manners.

246
247 Impact of age on antibody Fc effector functions

248 We next investigated if Fc domain features were dependent on age as we had observed with Fab
249 domain mediated neutralization. We observed a negative relationship between RBD specific IgG
250 binding to FcγRIIIa/CD16a, FcγRIIa/CD32a and FcγRIIb/CD32b with age (Figure 4 A-C) by linear
251 regression taking sex into account (Figure 4D). In contrast, no statistically significant relationships
252 between age and Fc receptor binding to antibodies targeting control antigens from other
253 pulmonary viruses respiratory syncytial virus (RSV) and influenza (Flu) and the negative control
254 *Bacillus anthracis* (Anthrax) were seen (Figure 4D). Consistent with neutralization data, we
255 observed that age negatively correlated with RBD specific IgG mediated NK cell CD107a

256 degranulation (Figure 4E) and intracellular IFN γ and TNF α production at varying levels
257 (Supplemental Figure 5 and Figure 4F). In comparison, the relationships between age and RBD
258 specific ADCP (Figure 4G), ADNP (Figure 4H) as well as ADCD (Supplemental Figure 5) were
259 non-significant. Consistent with differential IgG glycosylation linked to NK cell activation (Figure
260 3), asialylated fuosylated glycoforms in RBD compared to non-antigen specific IgG were
261 increased in those ≥ 65 years old (Figure 4I). These data showed that age negatively impacted
262 some but not all Fc effector functions as it did for neutralization, which is likely due to the
263 combination of decreased antibody levels and reduced antibody quality in differential
264 glycosylation and altered FcR engagement.

265

266 Polyclonal functional breadth and magnitude

267 Polyclonal antibody responses consist of multiple Fab and Fc domain features that interact to
268 influence disease outcomes. To begin to assess the collective functionality for each vaccinee
269 sample, we calculated the breadth of neutralization across all five SARS-CoV-2 isolates tested
270 (Supplemental Figure 5A). In addition, we Z score transformed data from Fc assays to enable
271 comparisons between effector functions and summarization of the cumulative Fc functional
272 magnitude for each individual (Supplemental Figure 5B). To assess how Fc functionality related
273 to Fab activity, we grouped individuals by their neutralization breadth. We found that neutralization
274 of all variants (100%) was detectable in 28 of the 51 individuals, and those remaining
275 demonstrated 50-83% breadth (Figure 5A). Of those with $< 100\%$ neutralization breadth, the
276 cumulative Fc functional scores were low or negative. Of those with 100% neutralization breadth,
277 both positive and negative cumulative Fc functional scores were detected. Thus, high
278 neutralization breadth and potent Fc effector functions are linked. Moreover, Fc functionality
279 represented a source of immune variation in the presence of broad Fab mediated neutralization.

280

281 Because we observed that both neutralizing (Figure 1) and non-neutralizing (Figure 4) antibody
282 functions were dependent on age, we assessed age with respect to neutralization breadth. We
283 found that the median age for those with 100% neutralization was younger (39 years) compared
284 to those with <100% (64.5, 67.5 and 52 years for 50%, 67% and 83% neutralization, respectively)
285 (Figure 5A). Thus, both antibody Fab and Fc mediated breadth and potency diminished with age.
286
287 To focus on age categorically, we grouped individuals into those <65 and ≥ 65 . The cutoff of 65
288 years was chosen for three reasons: 1) 63.5 is the median age of the subgroup of individuals with
289 no detectable neutralization against Omicron (BA.2), the variant with the lowest overall activities
290 (Figure 1B), 2) the median ages of the two groups with the lowest neutralization breadths are 64.5
291 and 67.5 (Figure 5A) and 3) ≥ 65 is the definition of older adults used by the Center for Disease
292 Control and Prevention with respect to COVID-19 vaccine administration guidelines (Bialek et al.,
293 2020). We calculated the polyfunctional breadth for each vaccinee by enumerating the proportion
294 of detectable SARS-CoV-2 neutralizing and non-neutralizing responses to categorize individuals
295 as high, medium, and low responders (Supplemental Figure 5C). We observed that most
296 individuals <65 had high polyfunctional breadth while those ≥ 65 had low or medium (Figure 5B).
297 This difference in breadth was not noted with groupings by sex (Figure 5C). In addition to antibody
298 breadth, we evaluated polyfunctional magnitude using vaccine specific neutralizing and non-
299 neutralizing antibody Z score data. We found that the extent of all antibody functions except for
300 ADCP was diminished in the ≥ 65 compared to <65 group (Figure 5D). Because polyfunctional
301 antibody responses are comprised of multiple activities that potentially occur concurrently to
302 influence outcomes of infection, we assessed the coordination between antibody features and
303 functions in these two age groups. We found more coordination in those <65 compared to ≥ 65
304 (Figure 5E). Thus, the breadth, magnitude, and coordination of BNT162b2 induced neutralizing
305 and non-neutralizing antibody polyfunctionality diverge with respect to the age of 65 years.

306 Discussion

307 In this study we show that two doses of the BNT162b2 mRNA vaccine elicited coordinated
308 neutralizing and non-neutralizing antibody functions. The presence of vaccine specific
309 antibodies is critical but neutralizing and non-neutralizing antibody functions are driven by
310 quality as well as quantity. Thus, titers correlated with neutralizing activity (Figure 1A) and
311 vaccine induced neutralizing responses against live clinical isolates of SARS-CoV-2 and five
312 distinct variants decreased with age (Figure 1B). Neutralization correlated with Fc γ R111a/CD16a
313 activation of natural killer cells that leads to cellular cytotoxicity but not phagocytosis or
314 complement deposition (Figure 2). Engagement with Fc γ R111a/CD16a was associated with post-
315 translational vaccine specific IgG afucosylation and sialylation (Figure 3H-K) which diverge with
316 age (Figure 4I). Antibody functions were diminished among those aged ≥ 65 : neutralization
317 breadth across variants, overall Fc functional potency, and coordination between neutralizing
318 and non-neutralizing antibody activities (Figure 5B, D, E), demonstrating compromised vaccine-
319 induced polyfunctionality. Neutralizing activity and antibody titers are measured in vaccine
320 studies to gauge effectiveness at blocking infection. The findings from this study show that non-
321 neutralizing antibody effector functions are immune correlates that could inform on the potential
322 of vaccines to prevent disease, a target which is of growing importance with the continual
323 emergence of new variants that subvert neutralization.

324
325 Non-neutralizing antibody functions are mediated by immune complexing and binding between
326 the Fc domain and Fc receptors. Thus, even with reduced Fab domain avidity for mutated viral
327 proteins such as spike, vaccine induced non-neutralizing Fc functions could remain robust. Our
328 data show that neutralizing activities across all variants are lower compared to wildtype virus
329 (Figure 1B), suggesting that effectiveness in preventing infection is significantly compromised.
330 However, even with increased case numbers of infection due to variants, epidemiological data

331 show relatively strong vaccine protection against disease and hospitalization (Altarawneh et al.,
332 2022; Andrews et al., 2022; Collie et al., 2022; Nasreen et al., 2022; Tang et al., 2021). Our
333 data show that the correlation between titers and neutralizing activities was decreased across
334 different variants, and the relationships with non-neutralizing functions, specifically ADNKA
335 partially overlapped (Figure 5E).

336
337 In line with these observations from human studies, data from animal models demonstrate that
338 *in vitro* neutralization does not uniformly correlate with *in vivo* protection against disease
339 (Schafer et al., 2021). Moreover, enhancement of non-neutralizing Fc effector functions delay
340 viral spread synergistically with neutralizing activity in mice (Beaudoin-Bussieres et al., 2022). In
341 humans, our results show that many non-neutralizing Fc effector functions were elicited by
342 vaccination but antibody dependent NK cell activation that leads to cellular cytotoxicity
343 specifically linked to neutralization across wildtype and SARS-CoV-2 variants (Figure 2). Thus,
344 along with inhibiting viral entry by neutralization, vaccine specific antibodies via Fc γ RIIIa/CD16a
345 expressing NK cells, monocytes and macrophages could target cytotoxicity against airway
346 epithelial cells already infected with SARS-CoV-2 to prevent viral spread and disease.

347
348 In natural infection, Fc γ RIIIa/CD16a is associated with disease severity (Chakraborty et al.,
349 2021; Chakraborty et al., 2022; Hoepel et al., 2021; Junqueira et al., 2022; Larsen et al., 2021).
350 While our data here do not include individuals with severe COVID-19 disease, the nature of
351 polyclonal antibodies generated during natural infection diverge from vaccination. First, the
352 antigenic repertoire after natural infection likely contains non-RBD specific antibody responses
353 that are absent after vaccination. Second, antibody titers are likely diminished with exposure to
354 lower amounts of antigen from mild and asymptomatic infection compared to severe disease
355 and vaccination (Dufloo et al., 2021). Thus, Fc γ RIIIa/CD16a activities from immunity generated

356 after natural infection could confer different downstream consequences compared to
357 vaccination.

358
359 Post-translational IgG glycosylation influences Fc receptor binding and activation. Along with
360 afucosylation that enhances Fc γ RIIIa/CD16a engagement which is also observed in severe
361 COVID-19 disease, our data from whole vaccine specific IgG show that sialic acid could also
362 contribute (Figure 3H and Figure 5). As such, sialylation on vaccine specific IgG could further
363 modify Fc γ RIIIa/CD16a activation. The study of IgG glycosylation has focused primarily on N297
364 of the Fc domain (Chakraborty et al., 2021; Chakraborty et al., 2022; Farkash et al., 2021;
365 Hoepel et al., 2021; Larsen et al., 2021), not accounting for the 20% of polyclonal IgG modified
366 on the Fab domain (van de Bovenkamp et al., 2016). Our evaluation of whole IgG suggests that
367 glycans from both Fab and Fc domains contribute to Fc effector functions by indirectly and
368 directly affecting Fc receptor interactions (He et al., 2016; Shi et al., 2019; Yamaguchi et al.,
369 2022). Thus, how an Fc receptor is activated by differential antibody glycosylation could be
370 critical in determining the outcomes of downstream immune responses.

371
372 The factors which predict vaccine response at an individual level are the subject of intense
373 study. Several lines of evidence support that age is one important factor (Bates et al., 2021a;
374 Collier et al., 2021; Farkash et al., 2021). Our study was designed to look specifically at the
375 contribution of age to non-neutralizing antibody activities from vaccination. In the elderly
376 compared to younger individuals, virus specific memory B cells and antibody titers persist longer
377 than neutralizing activity (Jeffery-Smith et al., 2022). Thus, loss of neutralization with a shift
378 towards more dependence on non-neutralizing antibody activity could be a hallmark of
379 immunosenescence. As such, monitoring non-neutralizing in addition to neutralizing functions
380 could help determine the need and dose of booster vaccinations for this population. Moreover,

381 approaches using adjuvants to enhance vaccine mediated non-neutralizing antibody functions
382 such as Fc γ R111a/CD16a could be beneficial (Coler et al., 2018).

383
384 With respect to the broader population, analyses of longitudinal and cross-sectional studies
385 involving vaccination and infection show that non-neutralizing functions including NK cell activity
386 and ADCC are sustained longer than neutralization (Fuentes-Villalobos et al., 2022; Lee et al.,
387 2021; Tso et al., 2021). Modeling of neutralization decay predicts that protection from infection
388 is lost but protection from severe disease is retained (Khoury et al., 2021). This divergence
389 between neutralizing titers and immune protection is likely due to multiple factors including viral
390 fitness (Mlcochova et al., 2021; Wang et al., 2021; Weisblum et al., 2020), T cell activities
391 (Keeton et al., 2022) as well as non-neutralizing responses such as the Fc γ R111a/CD16a
392 functions observed here. Thus, enhancing non-neutralizing activities elicited by vaccines could
393 provide longer lasting protection against disease independent of altering vaccine antigens to
394 target each new variant.

395
396 Current CDC vaccine recommendations for healthy adults <50 involve three total doses and for
397 those \geq 50, four. At the time of this writing, 91.8% of the US population \geq 65 who have received
398 two doses, 70.4% three and 39.1% four (CDC, 2022). Outside the US, many parts of the world
399 still have limited access to vaccine and have lower rates of vaccination. Our data support the
400 assertion that for those elderly individuals with two doses of BNT162b2, immunity is suboptimal
401 because neutralizing and non-neutralizing antibody activities are restricted. The effects of
402 additional doses of vaccines using antigens from the original SARS-CoV-2 strain or Omicron
403 and infection on top of vaccination that generates hybrid immunity remain to be fully defined but
404 likely encompass enriched neutralization breadth and Fc potency (Collier et al., 2021; Farkash
405 et al., 2021; Richardson et al., 2022). How much protection is enhanced is a subject of active

406 discourse (Atmar et al., 2022; Regev-Yochay et al., 2022). Evaluating the breadth, magnitude
407 and coordination of polyclonal antibody functions (Figure 5) will enhance resolution of correlates
408 of protection, particularly in the context of variants where the effect of neutralizing activity is
409 likely limited. There is growing evidence that adjuvants and antigens can be used to skew
410 immune responses including antibody glycosylation and Fc effector functions for rational
411 vaccine design (Bartsch et al., 2020; Boudreau et al., 2020; Mahan et al., 2016; Oefner et al.,
412 2012). Approaches that leverage the collaboration between antibody Fab and Fc domain
413 functions could improve vaccine efficacy against variants for all, and specifically for vulnerable
414 populations with difficulty generating neutralizing responses such as the elderly.

415

416 Limitations of the study

417 Limitations to this study include sample size, the lack of ethnicity, race and clinical data and the
418 homogeneity of the population examined with all participants being employees of a local health
419 care system. These cohort characteristics limited the ability to resolve more subtle differences
420 and extrapolate across a diverse array of individuals but also minimized potential sources of
421 confounding variables, likely facilitating the discovery of relationships between antibody features
422 that would otherwise be difficult to discern due to the complexity and heterogeneity of
423 polyfunctional antibodies. The absence of infection was not determined by molecular
424 microbiological diagnostics but rather serologically by the lack of detectable nucleocapsid
425 (Supplemental Figure 1A), RBD specific antibodies prior to vaccination (Bates et al., 2021a) and
426 clinical history. As such, it is plausible that individuals with asymptomatic infections are included.
427 However, the dominant immune responses measured were likely due to vaccination given the
428 narrow window between the second vaccine dose and sample collection time (14-15 days). As
429 the cohort was sex balanced, the major known phenotypic variation in this group was age (21 to
430 82 years).

431

432 **STAR Methods**

433 **RESOURCE AVAILABILITY**

434

435 ***Lead contact***

436 Further information and requests for resources and reagents should be directed to and will be
437 fulfilled by the lead contact, Lenette Lu (lenette.lu@utsouthwestern.edu).

438

439 ***Materials availability***

440 No unique reagents were generated during the course of this study.

441

442 ***Data and code availability***

443 The dataset generated during this study is available upon reasonable request. This paper does
444 not report original code. Any additional information required to reanalyze the data reported in
445 this paper is available from the lead contact upon request.

446

447 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

448

449 **Cohort**

450 Study participants (n=51) were enrolled between December 2020 and February 2021 at Oregon
451 Health & Science University immediately after receiving their first dose of BNT162b2 vaccine.
452 Participants received a second vaccine dose between 21±1 days following the first dose, then
453 returned 14-15 days later for follow up. Whole blood was collected in serum tubes (BD) and
454 serum isolated by centrifugation 1000xg for 10min. Sera were heat inactivated at 65°C for
455 30min then frozen at -20°C. This study was conducted in accordance with the Oregon Health &
456 Science University Institutional Review Board with written informed consent from all participants,

457 and approved by the UT Southwestern Medical Center Institutional Review Board. Written
458 informed consent was received from all study participants prior to participation.

459

460 **Cell Lines**

461 Vero E6 cells were purchased from ATCC (ATCC VERO C1008), grown at 37C, 5% CO₂ and
462 maintained in Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum,
463 1% penicillin/streptomycin, 1% non-essential amino acids. THP-1 cells were purchased from
464 ATCC (ATCC TIB-202), grown at 37C, 5% CO₂ and maintained in RPMI-1640 supplemented
465 with 10% fetal bovine serum, 2mM L-glutamine, 10mM HEPES, and 0.05 mM β-
466 mercaptoethanol. CD16.NK-92 (ATCC PTA-6967) were purchased from ATCC (ATCC PTA-
467 6967), grown at 37C, 5% CO₂ and maintained in in MEM-α supplemented with 12.5% FBS,
468 12.5% horse serum, 1.5g/L sodium bicarbonate, 0.02mM folic acid, 0.2mM inositol, 0.1 mM 2-β-
469 mercaptoethanol, 100U/mL recombinant IL-2.

470

471 **Primary Immune Cells**

472 Fresh peripheral blood was collected at UT Southwestern from healthy volunteers. All were over
473 18 and de-identified prior to blood processing. Neutrophils isolated from peripheral blood were
474 maintained at 37C, 5% CO₂ in RPMI with 10% fetal bovine serum, L-glutamine, and HEPES.
475 The study was approved by the UT Southwestern Medical Center Institutional Review Board.
476 Written informed consent was received from all study participants prior to participation.

477

478 **METHOD DETAILS**

479

480 **Virus**

481 SARS-CoV-2 clinical isolates were passaged once before use in neutralization assays: USA-
482 WA1/2020 [original strain] (BEI Resources NR-52281); USA/CA_CDC_5574/2020 [B.1.1.7] (BEI

483 Resources NR-54011); hCoV-54 19/South Africa/KRISP-K005325/2020 [B.1.351] (BEI
484 Resources NR-54009); hCoV-19/Japan/TY7-503/2021 [P.1] (BEI Resources NR-54982); hCoV-
485 19/USA/PHC658/2021 [B.1.617.2] (BEI Resources NR-55611); and hCoV-19/USA/CO-CDPHE-
486 2102544747/2021 [B.1.1.529 - BA.2] (BEI Resources NR-56520). Isolates were propagated in
487 Vero E6 cells for 24 to 72hrs until cultures displayed at least 20% cytopathic effect (CPE), as
488 previously described .

489

490 **Enzyme Linked Immunosorbent Assays (ELISA)**

491 ELISAs were performed as described (Bates et al., 2021b). Plates were coated overnight at 4°C
492 with 1 mg/mL recombinant SARS-CoV-2 spike receptor binding domain (RBD) protein (Bates et
493 al., 2021c) (BEI Resources NR-52309) or recombinant SARS-CoV-2 nucleocapsid (N) protein
494 (BEI Resources NR-53797). Serum dilutions (6 x 3-fold for RBD, 6 x 4-fold for N) in duplicate
495 were prepared in 5% milk powder, 0.05% Tween-20, in phosphate buffered saline (PBS),
496 starting at 1:1600 (pan-Ig), 1:50 (IgA), 1:200 (IgG). The secondary antibodies used were pan-Ig
497 (1:10,000 anti-human GOXHU IgG/A/M-HRP, A18847 Invitrogen), IgA (1:3,000 anti-human IgA-
498 HRP, 411002 Biolegend), and IgG (1:3,000 anti-human IgG-HRP 555788, BD Biosciences).
499 Plates were developed with o-phenylenediamine (OPD) (ThermoScientific). Absorbance at
500 492nm was measured on a CLARIOstar plate reader and normalized by subtracting the average
501 of negative control wells and dividing by the highest concentration from a positive control
502 dilution series. ELISA EC50 values were calculated by fitting normalized A492 as described
503 (Bates et al., 2021b). The limit of detection (LOD) was defined by the lowest dilution tested for
504 RBD and half of the lowest dilution for N. Values below the LOD were set to LOD – 1.

505

506 **Focus Reduction Neutralization Test (FRNT)**

507 Focus forming assays were performed as described (Bates et al., 2021b). Sub-confluent Vero
508 E6 cells were incubated for 1 hour with 30 µL of diluted sera (5 x 4-fold starting at 1:20) which

509 was pre-incubated for 1 hour with 100 infectious viral particles per well. Samples were tested in
510 duplicate. Wells were covered with 150 μ L of overlay media containing 1% methylcellulose and
511 incubated for 24hrs, 48hrs for Omicron. Plates were fixed by soaking in 4% formaldehyde in
512 PBS for 1 hour at room temperature. After permeabilization with 0.1% BSA, 0.1% saponin in
513 PBS, plates were incubated overnight at 4°C with primary antibody (1:5,000 anti-SARS-CoV-2
514 alpaca serum, 1:2,000 for Omicron) (Capralogics Inc) (Bates et al., 2021b). Plates were then
515 washed and incubated for 2hrs at room temperature with secondary antibody (1:20,000 anti-
516 alpaca-HRP, 1:5,000 for Omicron) (NB7242 Novus) and developed with TrueBlue (SeraCare)
517 for 30min. Foci were imaged with a CTL Immunospot Analyzer, enumerated using the viridot
518 package (Katzelnick et al., 2018) and percent neutralization calculated relative to the average of
519 virus-only wells for each plate. FRNT50 values were determined by fitting percent neutralization
520 to a 3-parameter logistic model as described previously (Bates et al., 2021b). The limit of
521 detection (LOD) was defined by the lowest dilution tested, values below the LOD were set to
522 LOD – 1. Duplicate FRNT50 values were first calculated separately to confirm values were
523 within 4-fold. When true, a final FRNT50 was calculated by fitting to combined replicates.

524

525 **Fc receptor binding assays**

526 Fc receptor binding assays were performed as described with modifications (Brown et al.,
527 2017). Carboxylated microspheres (Luminex) were coupled with recombinant SARS-CoV-2
528 RBD (Bates et al., 2021c)(BEI Resources NR-52309) by covalent NHS-ester linkages via EDC
529 (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride, Thermo Scientific Pierce) and
530 Sulfo-NHS (N-hydroxysulfosuccinimide) (Thermo Scientific) per the manufacturer's instructions.
531 A mixture of influenza antigens from strain H1N1 (NR-20083 and NR-51702, BEI Resources),
532 H5N1 (NR-12148, BEI Resources), H3N2, B Yamagata lineage, and B Victoria lineage (NR-
533 51702, BEI Resources) was used as a control. A mixture of recombinant *Bacillus anthracis*
534 antigens (Anthrax Protective Antigen, NR-36208 BEI Resources; Anthrax Lethal Factor, NR-

535 28544 BEI Resources; Anthrax Edema Factor, NR-36210 BEI Resources) and a separate
536 mixture of recombinant Respiratory Syncytial Virus antigens (G protein from strain B1, NR-
537 31098 BEI Resources; F protein from strain B1, NR-31097 BEI Resources; G protein from strain
538 A2, NR-31096 BEI Resources) were also used as controls. Antigen-coupled microspheres
539 (1250 beads per well) were incubated with serially diluted sera (1:100, 1:1000, 1:10000) in 96-
540 well Bioplex Pro Flat Bottom plates (Bio-Rad) at 4°C for 16hrs. Recombinant Fc receptors
541 (FcγRIIIa/CD16a, FcγRIIa/CD32a, FcγRIIb/CD32b, R&D Systems) were fluorescently labeled
542 with PE (Abcam) before addition to bead bound antigen specific immune complexes. After 2hrs
543 of incubation at room temperature, the beads were washed with PBS with 0.05% Tween20 and
544 antigen specific antibody bound Fc receptor measured on a on a MAGPIX instrument containing
545 xPONENT4.2 software (Luminex). The background signal, defined as MFI of microspheres
546 incubated with PBS, was subtracted. Representative data from one dilution was chosen by the
547 highest signal to noise ratio for further analyses.

548

549 **Non-antigen and RBD-specific IgG glycosylation**

550 Non-antigen and RBD specific IgG glycans were purified and relative levels quantified as
551 described with modifications (Mahan et al., 2015; Varadi et al., 2014). Recombinant RBD
552 protein (BEI Resources NR-52309) (Bates et al., 2021c) was biotinylated with sulfosuccinimidyl-
553 6-[biotinamido]-6-hexanamido hexanoate (sulfo-NHS-LC-LC biotin; ThermoScientific) and
554 coupled to streptavidin beads (New England Biolabs). Patient sera were incubated with RBD-
555 coupled beads and excess sera washed with PBS (Sigma). Bead-bound RBD-specific
556 antibodies then eluted using 100mM citric acid (pH 3.0) and neutralized with 0.5M potassium
557 phosphate (pH 9.0). Non-antigen specific or RBD-specific IgG were purified from the serum or
558 eluted RBD-specific antibodies respectively by protein G beads (Millipore). Purified IgG was
559 denatured and treated with PNGase enzyme (New England Biolabs) for 12hrs at 37°C to
560 release glycans.

561

562 To isolate bulk IgG glycans, proteins were removed by precipitation using ice cold 100% ethanol
563 at -20°C for 10min. To isolated RBD-specific IgG glycans, Agencourt CleanSEQ beads
564 (Beckman Coulter) were used to bind glycans in 87.5% acetonitrile (Fisher Scientific). The
565 supernatant was removed, glycans eluted from beads with HPLC grade water (Fisher Scientific)
566 and dried by centrifugal force and vacuum (CentriVap). Glycans were fluorescently labeled with
567 a 1.5:1 ratio of 50mM APTS (8-aminoinopyrene-1,3,6-trisulfonic acid, ThermoFisher) in 1.2M
568 citric acid and 1M sodium cyanoborohydride in tetrahydrofuran (Fisher Scientific) at 55°C for
569 3hrs. The labeled glycans were dissolved in HPLC grade water (Fisher Scientific) and excess
570 unbound APTS was removed using Agencourt CleanSEQ beads and Bio-Gel P-2 (Bio-rad) size
571 exclusion resin. Glycan samples were run with a LIZ 600 DNA ladder in Hi-Di formamide
572 (ThermoFisher) on an ABI 3500xL DNA sequencer and analyzed with GlycanAssure Data
573 Acquisition Software v.1.0. Each glycoform was separated by peaks and identified based on
574 glycan standard libraries (GKSP-520, Agilent). The relative abundance of each glycan for each
575 individual sample was determined as (area under curve of each glycan)/ (sum of area under
576 curve of all individual glycans).

577

578 **Antibody dependent cellular phagocytosis (ADCP)**

579 The THP-1 (TIB-202, ATCC) phagocytosis assay of antigen-coated beads was conducted as
580 described with modifications (Lu et al., 2016). SARS-CoV-2 RBD recombinant protein (BEI
581 Resources NR-52309) (Bates et al., 2021c) was biotinylated with Sulfo-NHS-LC Biotin (Thermo
582 Fisher), then incubated with 1 µm fluorescent neutravidin beads (Invitrogen) at 4°C for 16hrs.
583 Excess antigen was washed away and RBD-coupled neutravidin beads were resuspended in
584 PBS-0.1% bovine serum albumin (BSA). RBD-coupled beads were incubated with serial
585 dilutions of sera (1:100, 1:500 and 1:2500) in duplicate for 2hrs at 37°C. THP1 cells (1×10^5 per
586 well) were then added. Plasma opsonized RBD-coupled beads and THP1 cells were incubated

587 at 37°C for 16hrs. Cells were then washed once and fixed with 4% PFA. Bead uptake was
588 measured on a BD LSRFortessa (SCC) equipped with high-throughput sampler and analyzed
589 by FlowJo10. Phagocytic scores were calculated as the integrated median fluorescence
590 intensity (MFI) (% bead-positive frequency × MFI/10,000) (Darrah et al., 2007). Representative
591 data from one dilution was chosen by the highest signal to noise ratio for further analyses.

592

593 **Antibody dependent neutrophil phagocytosis (ADNP)**

594 The neutrophil phagocytosis assay of antigen-coated beads was conducted as described with
595 modifications (Lu et al., 2016). Whole healthy donor blood was mixed with equal volume 3%
596 dextran-500 (Thermo Fisher) and incubated for 25 min at room temperature to lyse and pellet
597 the red blood cells. Leukocytes were removed and washed in endotoxin-free sterile water
598 (Cytiva), followed by 1.8% NaCl (Thermo scientific) and then Hanks' balanced salt solution
599 without calcium and magnesium (Thermo Fisher). RBD conjugated beads, as described above,
600 were incubated with serial dilution of sera (1:100, 1:500 and 1:2500) for 2hrs at 37°C. Isolated
601 neutrophils (1×10^5 per well) were added and incubated for 2hrs at 37°C. Bead uptake was
602 measured on a BD LSRFortessa (SCC) equipped with high-throughput sampler and analyzed
603 by FlowJo10. Phagocytic scores were calculated as the integrated median fluorescence
604 intensity (MFI) (% bead-positive frequency × MFI/1,000). The purity of neutrophils was
605 confirmed by staining with CD66b (BioLegend). Sera samples were tested in two independent
606 experiments with neutrophils from two different HIV negative healthy donors. The mean of the
607 data from both donors was used for further analysis. Representative data from one dilution was
608 chosen by the highest signal to noise ratio for further analyses.

609

610 **Antibody dependent complement deposition (ADCD)**

611 The ADCD assay was performed as described with modifications (Fischinger et al., 2019).
612 Carboxylated microspheres (Luminex) were coupled with SARS-CoV-2 RBD protein (Bates et

613 al., 2021c) (NR-52309 BEI Resources) by covalent NHS-ester linkages via EDC (1-Ethyl-3-[3-
614 dimethylaminopropyl]carbodiimide hydrochloride, Thermo Scientific Pierce) and Sulfo-NHS (N-
615 hydroxysulfosuccinimide, Thermo Scientific) per manufacturer instructions. A mixture of
616 influenza antigens from strains H1N1 (NR-20083 and NR-51702, BEI Resources), H5N1 (NR-
617 12148, BEI Resources), H3N2, B Yamagata lineage, and B Victoria lineage (NR-51702, BEI
618 Resources) was used as a control. Serum samples were heated at 56°C for 30min. Antigen-
619 coated microspheres (1250 per well) were added to a 96-well Bioplex Pro Flat Bottom plates
620 (Bio-Rad) and incubated with serial dilutions of sera (1:10, 1:50 and 1:250) in duplicate at 4°C
621 for 16hrs. Freshly resuspended lyophilized guinea pig complement (Cedarlane) diluted 1:60 was
622 added to the plate for 20min at 37°C. After washing off excess complement three times
623 with 15mM EDTA, anti-C3 PE-conjugated goat polyclonal IgG (MP Biomedicals) was added. The
624 beads were then washed and C3 deposition quantified on a MAGPIX instrument containing
625 xPONENT4.2 software (Luminex). The background signal, defined as MFI of microspheres
626 incubated with PBS, was subtracted. Representative data from one dilution was chosen by the
627 highest signal to noise ratio for further analyses.

628

629 **Antibody dependent NK cell activation (ADNKA)**

630 ADNKA assay was performed as described with modifications (Gunn et al., 2020). ELISA plates
631 were coated with recombinant RBD antigen (300 ng/well) (Bates et al., 2021c) (BEI Resources
632 NR-52309). Wells were washed, blocked, and incubated with serial dilutions of sera (1:10, 1:30,
633 1:90) in duplicate for 2hrs at 37°C prior to adding CD16a.NK-92 cells (PTA-6967, ATCC) ($5 \times$
634 10^4 cells/well) for 5hrs with brefeldin A (Biolegend), Golgi Stop (BD Biosciences) and anti-
635 CD107a (clone H4A3, BD Biosciences). Cells were stained with anti-CD56 (clone 5.1H11, BD
636 Biosciences) and anti-CD16 (clone 3G8, BD Biosciences) and fixed with 4% PFA. Intracellular
637 cytokine staining to detect IFN γ (clone B27, BD Biosciences) and TNF α (clone Mab11, BD
638 Biosciences) was performed in permeabilization buffer (Biolegend). Markers were measured

639 using a BD LSRFortessa and analyzed by FlowJo10. CD16 expression was confirmed in all
640 cells. NK cell degranulation and activation were calculated as percent of CD56+NK cells
641 positive for CD107a, or IFN γ or TNF α expression. Representative data from one dilution was
642 chosen by the highest signal to noise ratio for further analyses.

643

644 **QUANTIFICATION AND STATISTICAL ANALYSIS**

645 Statistical analysis and graphing were performed using Stata17 and GraphPad Prism9.0. Data
646 are summarized using the descriptive measures median, minimum, maximum and percent (%).
647 Wilcoxon matched pair signed rank tests were used to compare neutralization of live SARS-
648 CoV-2 variants (Figure 1B) and glycoforms between antigen non-specific and RBD specific IgG
649 (Figures 3C-F, Supplemental Figure 3D-E). Mann-U-Whitney tests were used to compare the
650 neutralization of live SARS-CoV-2 variants between male and female (Supplemental Figure 1C).
651 Spearman rank correlations were used to examine bivariate associations between variables
652 (Figure 2 and 5E, Supplemental Figure 1D and 2). Simple linear regression was used to
653 examine the relationship between IgG glycoforms as the independent and Fc functional profiles
654 as the dependent variables (Figure 3H-K and Supplemental Figure 4). Multiple robust
655 regression models were used to adjust for the effect of age and sex when comparing the study
656 variables between individuals (Figure 1A, C-H, Figure 4, and Supplemental Figure 5). Z scores
657 of each individual Fc feature was calculated and then summed to generate the cumulative Fc
658 functional magnitude (Figure 5A, Supplemental Figure 6B). For the radar plots (Figure 4I), Z
659 scores of each individual RBD specific IgG glycoforms relative to bulk non-antigen specific IgG
660 glycoforms were calculated and the median values for each age group were plotted. For the
661 radar plots (Figure 5D), Z scores of each feature for each individual were calculated and the
662 median values for each group were plotted. All p values are two-sided, and $p < 0.05$ was
663 considered significant. In figures, asterisks denote statistical significance (* $p \leq 0.05$; ** $p \leq$
664 0.01 ; *** $p \leq 0.001$; **** $p \leq 0.0001$) with comparisons specified by connecting lines.

665

666

667 **Acknowledgements**

668 This study was funded by a grant from the M. J. Murdock Charitable Trust (to MEC), an
669 unrestricted grant from the OHSU Foundation (to MEC), the NIH training grant T32HL083808
670 (to TAB), NIH grant R011R01AI141549-01A1 (to FGT), OHSU Innovative IDEA grant 1018784
671 (to FGT), NIH grant R01AI145835 (to WBM), Burroughs Wellcome Fund UT Southwestern
672 Training Resident Doctors as Innovators in Science (to YJK), pilot project grant from the UT
673 Southwestern Department of Internal Medicine and Disease Oriented Scholars Award (to LLL).
674 We gratefully acknowledge the OHSU workforce members who participated in this study; the
675 OHSU COVID-19 serology study team and the OHSU occupational health department for their
676 efforts in recruitment and sample acquisition; the OHSU clinical laboratory under the direction of
677 Donna Hansel and Xuan Qin for SARS-Co-2 testing and reporting. We thank UTSW healthy
678 volunteers who donated their blood for neutrophil studies; Dawn Wetzel for efforts in
679 recruitment; Gabrielle Lessen for phlebotomy assistance; Ann McDonald for graphical
680 assistance. We are grateful for the support of the M.J. Murdock Charitable Trust and the OHSU
681 Foundation. The funders of the study had no role in study design, execution, analysis,
682 interpretation, or writing of this manuscript.

683

684 **Author Contributions**

685 LLL and FGT conceived, designed and supervised the work. TAB and PL designed, conducted
686 and analyzed experiments. MEC, WBM, DS, SKM coordinated sample and reagent collection.
687 SKM acquired and analyzed data. YJK, MT, CP, and DK analyzed the data. LLL, FGT, TAB,
688 and PL wrote the manuscript. YJK, MT, SKM, DK, WBM, MEC contributed to manuscript
689 revisions.

690

691

692

693 **References**

- 694 Adeniji, O.S., Giron, L.B., Purwar, M., Zilberstein, N.F., Kulkarni, A.J., Shaikh, M.W., Balk, R.A.,
695 Moy, J.N., Forsyth, C.B., Liu, Q., *et al.* (2021). COVID-19 Severity Is Associated with Differential
696 Antibody Fc-Mediated Innate Immune Functions. *mBio* *12*.
- 697 Altarawneh, H.N., Chemaitelly, H., Ayoub, H.H., Tang, P., Hasan, M.R., Yassine, H.M., Al-Khatib,
698 H.A., Smatti, M.K., Coyle, P., Al-Kanaani, Z., *et al.* (2022). Effects of Previous Infection and
699 Vaccination on Symptomatic Omicron Infections. *N Engl J Med* *387*, 21-34.
- 700 Alter, G., Ottenhoff, T.H.M., and Joosten, S.A. (2018). Antibody glycosylation in inflammation,
701 disease and vaccination. *Semin Immunol* *39*, 102-110.
- 702 Alter, G., Yu, J., Liu, J., Chandrashekar, A., Borducchi, E.N., Tostanoski, L.H., McMahan, K., Jacob-
703 Dolan, C., Martinez, D.R., Chang, A., *et al.* (2021). Immunogenicity of Ad26.COV2.S vaccine
704 against SARS-CoV-2 variants in humans. *Nature* *596*, 268-272.
- 705 Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall,
706 S., Groves, N., Dabrera, G., *et al.* (2022). Duration of Protection against Mild and Severe Disease
707 by Covid-19 Vaccines. *N Engl J Med* *386*, 340-350.
- 708 Arnold, J.N., Wormald, M.R., Sim, R.B., Rudd, P.M., and Dwek, R.A. (2007). The impact of
709 glycosylation on the biological function and structure of human immunoglobulins. *Annu Rev*
710 *Immunol* *25*, 21-50.
- 711 Atmar, R.L., Lyke, K.E., Deming, M.E., Jackson, L.A., Branche, A.R., El Sahly, H.M., Rostad, C.A.,
712 Martin, J.M., Johnston, C., Rupp, R.E., *et al.* (2022). Homologous and Heterologous Covid-19
713 Booster Vaccinations. *N Engl J Med* *386*, 1046-1057.
- 714 Bartsch, Y.C., Eschweiler, S., Leliavski, A., Lunding, H.B., Wagt, S., Petry, J., Lilienthal, G.M.,
715 Rahmoller, J., de Haan, N., Holscher, A., *et al.* (2020). IgG Fc sialylation is regulated during the
716 germinal center reaction following immunization with different adjuvants. *J Allergy Clin*
717 *Immunol* *146*, 652-666 e611.
- 718 Bartsch, Y.C., Wang, C., Zohar, T., Fischinger, S., Atyeo, C., Burke, J.S., Kang, J., Edlow, A.G.,
719 Fasano, A., Baden, L.R., *et al.* (2021). Humoral signatures of protective and pathological SARS-
720 CoV-2 infection in children. *Nat Med* *27*, 454-462.
- 721 Bates, T.A., Leier, H.C., Lyski, Z.L., Goodman, J.R., Curlin, M.E., Messer, W.B., and Tafesse, F.G.
722 (2021a). Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune
723 Serum Samples. *JAMA*.
- 724 Bates, T.A., Leier, H.C., Lyski, Z.L., McBride, S.K., Coulter, F.J., Weinstein, J.B., Goodman, J.R., Lu,
725 Z., Siegel, S.A.R., Sullivan, P., *et al.* (2021b). Neutralization of SARS-CoV-2 variants by
726 convalescent and BNT162b2 vaccinated serum. *Nat Commun* *12*, 5135.
- 727 Bates, T.A., Weinstein, J.B., Farley, S., Leier, H.C., Messer, W.B., and Tafesse, F.G. (2021c). Cross-
728 reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2. *Cell Rep* *34*, 108737.
- 729 Beaudoin-Bussieres, G., Chen, Y., Ullah, I., Prevost, J., Tolbert, W.D., Symmes, K., Ding, S.,
730 Benlarbi, M., Gong, S.Y., Tazuin, A., *et al.* (2022). A Fc-enhanced NTD-binding non-neutralizing
731 antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2
732 infection. *Cell Rep* *38*, 110368.

733 Begin, P., Callum, J., Jamula, E., Cook, R., Heddle, N.M., Tinmouth, A., Zeller, M.P., Beaudoin-
734 Bussieres, G., Amorim, L., Bazin, R., *et al.* (2021). Convalescent plasma for hospitalized patients
735 with COVID-19: an open-label, randomized controlled trial. *Nat Med* 27, 2012-2024.

736 Bialek, S., Boundy, E., Bowen, V., Chow, N., Cohn, A., Dowling, N., Ellington, S., Gierke, R., Hall,
737 A., MacNeil, J., *et al.* (2020). Severe Outcomes Among Patients with Coronavirus Disease 2019
738 (COVID-19) — United States, February 12–March 16, 2020. *Morbidity and Mortality Weekly*
739 *Report (MMWR)* 69, 343-346.

740 Boudreau, C.M., Yu, W.H., Suscovich, T.J., Talbot, H.K., Edwards, K.M., and Alter, G. (2020).
741 Selective induction of antibody effector functional responses using MF59-adjuvanted
742 vaccination. *J Clin Invest* 130, 662-672.

743 Brewer, R.C., Ramadoss, N.S., Lahey, L.J., Jahanbani, S., Robinson, W.H., and Lanz, T.V. (2022).
744 BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2. *Nat Immunol*
745 23, 33-39.

746 Brown, E.P., Dowell, K.G., Boesch, A.W., Normandin, E., Mahan, A.E., Chu, T., Barouch, D.H.,
747 Bailey-Kellogg, C., Alter, G., and Ackerman, M.E. (2017). Multiplexed Fc array for evaluation of
748 antigen-specific antibody effector profiles. *J Immunol Methods* 443, 33-44.

749 CDC (2022). COVID-19 Vaccinations in the United States. In COVID Data Tracker (Atlanta, GA: US
750 Department of Health and Human Services, CDC: Center for Disease Control and Prevention).

751 Chakraborty, S., Gonzalez, J., Edwards, K., Mallajosyula, V., Buzzanco, A.S., Sherwood, R.,
752 Buffone, C., Kathale, N., Providenza, S., Xie, M.M., *et al.* (2021). Proinflammatory IgG Fc
753 structures in patients with severe COVID-19. *Nat Immunol* 22, 67-73.

754 Chakraborty, S., Gonzalez, J.C., Sievers, B.L., Mallajosyula, V., Chakraborty, S., Dubey, M.,
755 Ashraf, U., Cheng, B.Y., Kathale, N., Tran, K.Q.T., *et al.* (2022). Early non-neutralizing,
756 afucosylated antibody responses are associated with COVID-19 severity. *Sci Transl Med* 14,
757 eabm7853.

758 Chung, A.W., Kumar, M.P., Arnold, K.B., Yu, W.H., Schoen, M.K., Dunphy, L.J., Suscovich, T.J.,
759 Frahm, N., Linde, C., Mahan, A.E., *et al.* (2015). Dissecting Polyclonal Vaccine-Induced Humoral
760 Immunity against HIV Using Systems Serology. *Cell* 163, 988-998.

761 Coler, R.N., Day, T.A., Ellis, R., Piazza, F.M., Beckmann, A.M., Vergara, J., Rolf, T., Lu, L., Alter, G.,
762 Hokey, D., *et al.* (2018). The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of
763 immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. *NPJ Vaccines*
764 3, 34.

765 Collie, S., Champion, J., Moultrie, H., Bekker, L.G., and Gray, G. (2022). Effectiveness of
766 BNT162b2 Vaccine against Omicron Variant in South Africa. *N Engl J Med* 386, 494-496.

767 Collier, D.A., Ferreira, I., Kotagiri, P., Datir, R.P., Lim, E.Y., Touizer, E., Meng, B., Abdullahi, A.,
768 Collaboration, C.-N.B.C.-., Elmer, A., *et al.* (2021). Age-related immune response heterogeneity
769 to SARS-CoV-2 vaccine BNT162b2. *Nature* 596, 417-422.

770 Darrah, P.A., Patel, D.T., De Luca, P.M., Lindsay, R.W., Davey, D.F., Flynn, B.J., Hoff, S.T.,
771 Andersen, P., Reed, S.G., Morris, S.L., *et al.* (2007). Multifunctional TH1 cells define a correlate
772 of vaccine-mediated protection against *Leishmania major*. *Nat Med* 13, 843-850.

773 Dufloo, J., Grzelak, L., Staropoli, I., Madec, Y., Tondeur, L., Anna, F., Pelleau, S., Wiedemann, A.,
774 Planchais, C., Buchrieser, J., *et al.* (2021). Asymptomatic and symptomatic SARS-CoV-2
775 infections elicit polyfunctional antibodies. *Cell Rep Med* 2, 100275.

776 Evans, J.P., Zeng, C., Qu, P., Faraone, J., Zheng, Y.M., Carlin, C., Bednash, J.S., Zhou, T., Lozanski,
777 G., Mallampalli, R., *et al.* (2022). Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1,
778 BA.1.1, and BA.2. *Cell Host Microbe*.

779 Farkash, I., Feferman, T., Cohen-Saban, N., Avraham, Y., Morgenstern, D., Mayuni, G., Barth, N.,
780 Lustig, Y., Miller, L., Shouval, D.S., *et al.* (2021). Anti-SARS-CoV-2 antibodies elicited by COVID-
781 19 mRNA vaccine exhibit a unique glycosylation pattern. *Cell Rep* 37, 110114.

782 Fischinger, S., Fallon, J.K., Michell, A.R., Broge, T., Suscovich, T.J., Streeck, H., and Alter, G.
783 (2019). A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies
784 to induce complement activation. *J Immunol Methods* 473, 112630.

785 Fuentes-Villalobos, F., Garrido, J.L., Medina, M.A., Zambrano, N., Ross, N., Bravo, F., Gaete-
786 Argel, A., Oyarzun-Arrau, A., Amanat, F., Soto-Rifo, R., *et al.* (2022). Sustained Antibody-
787 Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence. *Front*
788 *Immunol* 13, 796481.

789 Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., Yang, D., Miller, T.E., Feldman, J., Hauser, B.M.,
790 Caradonna, T.M., Clayton, K.L., Nitido, A.D., *et al.* (2021). COVID-19-neutralizing antibodies
791 predict disease severity and survival. *Cell* 184, 476-488 e411.

792 Garcia-Beltran, W.F., St Denis, K.J., Hoelzemer, A., Lam, E.C., Nitido, A.D., Sheehan, M.L.,
793 Berrios, C., Ofoman, O., Chang, C.C., Hauser, B.M., *et al.* (2022). mRNA-based COVID-19 vaccine
794 boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* 185, 457-466
795 e454.

796 Gorman, M.J., Patel, N., Guebre-Xabier, M., Zhu, A.L., Atyeo, C., Pullen, K.M., Loos, C., Goez-
797 Gazi, Y., Carrion, R., Jr., Tian, J.H., *et al.* (2021). Fab and Fc contribute to maximal protection
798 against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. *Cell*
799 *Rep Med* 2, 100405.

800 Group, R.C. (2021). Convalescent plasma in patients admitted to hospital with COVID-19
801 (RECOVERY): a randomised controlled, open-label, platform trial. *Lancet* 397, 2049-2059.

802 Gunn, B.M., Roy, V., Karim, M.M., Hartnett, J.N., Suscovich, T.J., Goba, A., Momoh, M., Sandi,
803 J.D., Kanneh, L., Andersen, K.G., *et al.* (2020). Survivors of Ebola Virus Disease Develop
804 Polyfunctional Antibody Responses. *J Infect Dis* 221, 156-161.

805 He, W., Tan, G.S., Mullarkey, C.E., Lee, A.J., Lam, M.M., Krammer, F., Henry, C., Wilson, P.C.,
806 Ashkar, A.A., Palese, P., *et al.* (2016). Epitope specificity plays a critical role in regulating
807 antibody-dependent cell-mediated cytotoxicity against influenza A virus. *Proc Natl Acad Sci U S*
808 *A* 113, 11931-11936.

809 Herman, J.D., Wang, C., Loos, C., Yoon, H., Rivera, J., Eugenia Dieterle, M., Haslwanter, D.,
810 Jangra, R.K., Bortz, R.H., 3rd, Bar, K.J., *et al.* (2021). Functional convalescent plasma antibodies
811 and pre-infusion titers shape the early severe COVID-19 immune response. *Nat Commun* 12,
812 6853.

813 Hoepel, W., Chen, H.J., Geyer, C.E., Allahverdiyeva, S., Manz, X.D., de Taeye, S.W., Aman, J.,
814 Mes, L., Steenhuis, M., Griffith, G.R., *et al.* (2021). High titers and low fucosylation of early
815 human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. *Sci Transl Med*
816 13.

817 Jeffery-Smith, A., Burton, A.R., Lens, S., Rees-Spear, C., Davies, J., Patel, M., Gopal, R., Muir, L.,
818 Aiano, F., Doores, K.J., *et al.* (2022). SARS-CoV-2-specific memory B cells can persist in the
819 elderly who have lost detectable neutralizing antibodies. *J Clin Invest* 132.

820 Junqueira, C., Crespo, A., Ranjbar, S., de Lacerda, L.B., Lewandrowski, M., Ingber, J., Parry, B.,
821 Ravid, S., Clark, S., Schimpf, M.R., *et al.* (2022). Fcγ-mediated SARS-CoV-2 infection of
822 monocytes activates inflammation. *Nature*.

823 Kaplonek, P., Cizmeci, D., Fischinger, S., Collier, A.R., Suscovich, T., Linde, C., Broge, T., Mann, C.,
824 Amanat, F., Dayal, D., *et al.* (2022). mRNA-1273 and BNT162b2 COVID-19 vaccines elicit
825 antibodies with differences in Fc-mediated effector functions. *Sci Transl Med*, eabm2311.

826 Katzelnick, L.C., Coello Escoto, A., McElvany, B.D., Chavez, C., Salje, H., Luo, W., Rodriguez-
827 Barraquer, I., Jarman, R., Durbin, A.P., Diehl, S.A., *et al.* (2018). Viridot: An automated virus
828 plaque (immunofocus) counter for the measurement of serological neutralizing responses with
829 application to dengue virus. *PLoS Negl Trop Dis* 12, e0006862.

830 Kawasuji, H., Morinaga, Y., Tani, H., Saga, Y., Kaneda, M., Murai, Y., Ueno, A., Miyajima, Y.,
831 Fukui, Y., Nagaoka, K., *et al.* (2021). Age-Dependent Reduction in Neutralization against Alpha
832 and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. *Microbiol Spectr* 9,
833 e0056121.

834 Keeton, R., Tincho, M.B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S.,
835 Bernstein, M., Karim, F., *et al.* (2022). T cell responses to SARS-CoV-2 spike cross-recognize
836 Omicron. *Nature* 603, 488-492.

837 Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao, K.,
838 Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody levels are highly
839 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 27, 1205-
840 1211.

841 Klingler, J., Lambert, G.S., Itri, V., Liu, S., Bandres, J.C., Enyindah-Asonye, G., Liu, X., Simon, V.,
842 Gleason, C.R., Kleiner, G., *et al.* (2021). Detection of Antibody Responses against SARS-CoV-2 in
843 Plasma and Saliva from Vaccinated and Infected Individuals. *medRxiv*.

844 Kurhade, C., Zou, J., Xia, H., Cai, H., Yang, Q., Cutler, M., Cooper, D., Muik, A., Jansen, K.U., Xie,
845 X., *et al.* (2022). Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of
846 BNT162b2 vaccine. *Nat Commun* 13, 3602.

847 Larsen, M.D., de Graaf, E.L., Sonneveld, M.E., Plomp, H.R., Nouta, J., Hoepel, W., Chen, H.J.,
848 Linty, F., Visser, R., Brinkhaus, M., *et al.* (2021). Afucosylated IgG characterizes enveloped viral
849 responses and correlates with COVID-19 severity. *Science* 371.

850 Lee, W.S., Selva, K.J., Davis, S.K., Wines, B.D., Reynaldi, A., Esterbauer, R., Kelly, H.G., Haycroft,
851 E.R., Tan, H.X., Juno, J.A., *et al.* (2021). Decay of Fc-dependent antibody functions after mild to
852 moderate COVID-19. *Cell Rep Med* 2, 100296.

853 Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S.C., Swanson, K.A., Cai, H., Cutler, M., Cooper, D., Muik,
854 A., *et al.* (2021). BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
855 *Nature* 596, 273-275.

856 Lofano, G., Gorman, M.J., Yousif, A.S., Yu, W.H., Fox, J.M., Dugast, A.S., Ackerman, M.E.,
857 Suscovich, T.J., Weiner, J., Barouch, D., *et al.* (2018). Antigen-specific antibody Fc glycosylation
858 enhances humoral immunity via the recruitment of complement. *Sci Immunol* 3.

859 Lu, L.L., Chung, A.W., Rosebrock, T.R., Ghebremichael, M., Yu, W.H., Grace, P.S., Schoen, M.K.,
860 Tafesse, F., Martin, C., Leung, V., *et al.* (2016). A Functional Role for Antibodies in Tuberculosis.
861 *Cell* 167, 433-443 e414.

862 Lu, L.L., Suscovich, T.J., Fortune, S.M., and Alter, G. (2018). Beyond binding: antibody effector
863 functions in infectious diseases. *Nat Rev Immunol* 18, 46-61.

864 Lucas, C., Klein, J., Sundaram, M.E., Liu, F., Wong, P., Silva, J., Mao, T., Oh, J.E., Mohanty, S.,
865 Huang, J., *et al.* (2021). Delayed production of neutralizing antibodies correlates with fatal
866 COVID-19. *Nat Med* 27, 1178-1186.

867 Lustig, Y., Sapir, E., Regev-Yochay, G., Cohen, C., Fluss, R., Olmer, L., Indenbaum, V.,
868 Mandelboim, M., Doolman, R., Amit, S., *et al.* (2021). BNT162b2 COVID-19 vaccine and
869 correlates of humoral immune responses and dynamics: a prospective, single-centre,
870 longitudinal cohort study in health-care workers. *Lancet Respir Med* 9, 999-1009.

871 Mahan, A.E., Jennewein, M.F., Suscovich, T., Dionne, K., Tedesco, J., Chung, A.W., Streeck, H.,
872 Pau, M., Schuitemaker, H., Francis, D., *et al.* (2016). Antigen-Specific Antibody Glycosylation Is
873 Regulated via Vaccination. *PLoS Pathog* 12, e1005456.

874 Mahan, A.E., Tedesco, J., Dionne, K., Baruah, K., Cheng, H.D., De Jager, P.L., Barouch, D.H.,
875 Suscovich, T., Ackerman, M., Crispin, M., *et al.* (2015). A method for high-throughput, sensitive
876 analysis of IgG Fc and Fab glycosylation by capillary electrophoresis. *J Immunol Methods* 417,
877 34-44.

878 Mlcochova, P., Kemp, S.A., Dhar, M.S., Papa, G., Meng, B., Ferreira, I., Datir, R., Collier, D.A.,
879 Albecka, A., Singh, S., *et al.* (2021). SARS-CoV-2 B.1.617.2 Delta variant replication and immune
880 evasion. *Nature* 599, 114-119.

881 Nasreen, S., Chung, H., He, S., Brown, K.A., Gubbay, J.B., Buchan, S.A., Fell, D.B., Austin, P.C.,
882 Schwartz, K.L., Sundaram, M.E., *et al.* (2022). Effectiveness of COVID-19 vaccines against
883 symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario.
884 *Nat Microbiol* 7, 379-385.

885 Nimmerjahn, F., and Ravetch, J.V. (2005). Divergent immunoglobulin g subclass activity through
886 selective Fc receptor binding. *Science* 310, 1510-1512.

887 Noori, M., Nejadghaderi, S.A., Arshi, S., Carson-Chahhoud, K., Ansarin, K., Kolahi, A.A., and
888 Safiri, S. (2022). Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies
889 against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in
890 vitro studies. *Rev Med Virol* 32, e2277.

891 Oefner, C.M., Winkler, A., Hess, C., Lorenz, A.K., Holecska, V., Huxdorf, M., Schommartz, T.,
892 Petzold, D., Bitterling, J., Schoen, A.L., *et al.* (2012). Tolerance induction with T cell-dependent
893 protein antigens induces regulatory sialylated IgGs. *J Allergy Clin Immunol* 129, 1647-1655
894 e1613.

895 Peschke, B., Keller, C.W., Weber, P., Quast, I., and Lunemann, J.D. (2017). Fc-Galactosylation of
896 Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-
897 Dependent Cytotoxicity. *Front Immunol* 8, 646.

898 Petrovic, T., Alves, I., Bugada, D., Pascual, J., Vuckovic, F., Skelin, A., Gaifem, J., Villar-Garcia, J.,
899 Vicente, M.M., Fernandes, A., *et al.* (2021). Composition of the immunoglobulin G glycome
900 associates with the severity of COVID-19. *Glycobiology* 31, 372-377.

901 Pincetic, A., Bournazos, S., DiLillo, D.J., Maamary, J., Wang, T.T., Dahan, R., Fiebiger, B.M., and
902 Ravetch, J.V. (2014). Type I and type II Fc receptors regulate innate and adaptive immunity. *Nat*
903 *Immunol* 15, 707-716.

904 Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland,
905 W.H., Porrot, F., Staropoli, I., Lemoine, F., *et al.* (2022). Considerable escape of SARS-CoV-2
906 Omicron to antibody neutralization. *Nature* 602, 671-675.

907 Quast, I., Keller, C.W., Maurer, M.A., Giddens, J.P., Tackenberg, B., Wang, L.X., Munz, C.,
908 Nimmerjahn, F., Dalakas, M.C., and Lunemann, J.D. (2015). Sialylation of IgG Fc domain impairs
909 complement-dependent cytotoxicity. *J Clin Invest* *125*, 4160-4170.

910 Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., Meltzer, L.,
911 Asraf, K., Cohen, C., Fluss, R., *et al.* (2022). Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine
912 against Omicron. *N Engl J Med*.

913 Richardson, S.I., Manamela, N.P., Motsoeneng, B.M., Kaldine, H., Ayres, F., Makhado, Z.,
914 Mennen, M., Skelem, S., Williams, N., Sullivan, N.J., *et al.* (2022). SARS-CoV-2 Beta and Delta
915 variants trigger Fc effector function with increased cross-reactivity. *Cell Rep Med* *3*, 100510.

916 Savage, H.R., Santos, V.S., Edwards, T., Giorgi, E., Krishna, S., Planche, T.D., Staines, H.M.,
917 Fitchett, J.R.A., Kirwan, D.E., Cubas Atienzar, A.I., *et al.* (2021). Prevalence of neutralising
918 antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and
919 meta-analysis. *PLoS Negl Trop Dis* *15*, e0009551.

920 Schafer, A., Muecksch, F., Lorenzi, J.C.C., Leist, S.R., Cipolla, M., Bournazos, S., Schmidt, F.,
921 Maison, R.M., Gazumyan, A., Martinez, D.R., *et al.* (2021). Antibody potency, effector function,
922 and combinations in protection and therapy for SARS-CoV-2 infection in vivo. *J Exp Med* *218*.

923 Scully, E.P., Haverfield, J., Ursin, R.L., Tannenbaum, C., and Klein, S.L. (2020). Considering how
924 biological sex impacts immune responses and COVID-19 outcomes. *Nat Rev Immunol* *20*, 442-
925 447.

926 Selva, K.J., van de Sandt, C.E., Lemke, M.M., Lee, C.Y., Shoffner, S.K., Chua, B.Y., Davis, S.K.,
927 Nguyen, T.H.O., Rowntree, L.C., Hensen, L., *et al.* (2021). Systems serology detects functionally
928 distinct coronavirus antibody features in children and elderly. *Nat Commun* *12*, 2037.

929 Shi, L., Liu, T., Gross, M.L., and Huang, Y. (2019). Recognition of Human IgG1 by Fcγ3 Receptors:
930 Structural Insights from Hydrogen-Deuterium Exchange and Fast Photochemical
931 Oxidation of Proteins Coupled with Mass Spectrometry. *Biochemistry* *58*, 1074-1080.

932 Suryadevara, N., Shrihari, S., Gilchuk, P., VanBlargan, L.A., Binshtein, E., Zost, S.J., Nargi, R.S.,
933 Sutton, R.E., Winkler, E.S., Chen, E.C., *et al.* (2021). Neutralizing and protective human
934 monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. *Cell*
935 *184*, 2316-2331 e2315.

936 Syed, A.M., Taha, T.Y., Tabata, T., Chen, I.P., Ciling, A., Khalid, M.M., Sreekumar, B., Chen, P.Y.,
937 Hayashi, J.M., Soczek, K.M., *et al.* (2021). Rapid assessment of SARS-CoV-2-evolved variants
938 using virus-like particles. *Science* *374*, 1626-1632.

939 Tang, P., Hasan, M.R., Chemaitelly, H., Yassine, H.M., Benslimane, F.M., Al Khatib, H.A.,
940 AlMukdad, S., Coyle, P., Ayoub, H.H., Al Kanaani, Z., *et al.* (2021). BNT162b2 and mRNA-1273
941 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nat Med* *27*,
942 2136-2143.

943 Tso, F.Y., Lidenge, S.J., Poppe, L.K., Pena, P.B., Privatt, S.R., Bennett, S.J., Ngowi, J.R.,
944 Mwaiselage, J., Belshan, M., Siedlik, J.A., *et al.* (2021). Presence of antibody-dependent cellular
945 cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma. *PLoS One* *16*, e0247640.

946 Ullah, I., Prevost, J., Ladinsky, M.S., Stone, H., Lu, M., Anand, S.P., Beaudoin-Bussieres, G.,
947 Symmes, K., Benlarbi, M., Ding, S., *et al.* (2021). Live imaging of SARS-CoV-2 infection in mice
948 reveals that neutralizing antibodies require Fc function for optimal efficacy. *Immunity* *54*, 2143-
949 2158 e2115.

950 van de Bovenkamp, F.S., Hafkenscheid, L., Rispens, T., and Rombouts, Y. (2016). The Emerging
951 Importance of IgG Fab Glycosylation in Immunity. *J Immunol* *196*, 1435-1441.

952 van Osch, T.L.J., Nouta, J., Derksen, N.I.L., van Mierlo, G., van der Schoot, C.E., Wuhrer, M.,
953 Rispens, T., and Vidarsson, G. (2021). Fc Galactosylation Promotes Hexamerization of Human
954 IgG1, Leading to Enhanced Classical Complement Activation. *J Immunol* *207*, 1545-1554.

955 Varadi, C., Lew, C., and Guttman, A. (2014). Rapid magnetic bead based sample preparation for
956 automated and high throughput N-glycan analysis of therapeutic antibodies. *Anal Chem* *86*,
957 5682-5687.

958 Vicente, M.M., Alves, I., Gaifem, J., Rodrigues, C.S., Fernandes, A., Dias, A.M., Stambuk, J.,
959 Petrovic, T., Oliveira, P., Ferreira-da-Silva, F., *et al.* (2022). Altered IgG glycosylation at COVID-19
960 diagnosis predicts disease severity. *Eur J Immunol*.

961 Vogel, A.B., Kanevsky, I., Che, Y., Swanson, K.A., Muik, A., Vormehr, M., Kranz, L.M., Walzer,
962 K.C., Hein, S., Guler, A., *et al.* (2021). BNT162b vaccines protect rhesus macaques from SARS-
963 CoV-2. *Nature* *592*, 283-289.

964 Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P.D.,
965 *et al.* (2021). Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* *593*, 130-
966 135.

967 Wang, Q., Guo, Y., Iketani, S., Nair, M.S., Li, Z., Mohri, H., Wang, M., Yu, J., Bowen, A.D., Chang,
968 J.Y., *et al.* (2022). Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and
969 BA.5. *Nature*.

970 Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J.C., Muecksch, F.,
971 Rutkowska, M., Hoffmann, H.H., Michailidis, E., *et al.* (2020). Escape from neutralizing
972 antibodies by SARS-CoV-2 spike protein variants. *Elife* *9*.

973 Winkler, E.S., Gilchuk, P., Yu, J., Bailey, A.L., Chen, R.E., Chong, Z., Zost, S.J., Jang, H., Huang, Y.,
974 Allen, J.D., *et al.* (2021). Human neutralizing antibodies against SARS-CoV-2 require intact Fc
975 effector functions for optimal therapeutic protection. *Cell* *184*, 1804-1820 e1816.

976 Writing Committee for the, R.-C.A.P.I., Estcourt, L.J., Turgeon, A.F., McQuilten, Z.K., McVerry,
977 B.J., Al-Beidh, F., Annane, D., Arabi, Y.M., Arnold, D.M., Beane, A., *et al.* (2021). Effect of
978 Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A
979 Randomized Clinical Trial. *JAMA* *326*, 1690-1702.

980 Yamaguchi, Y., Wakaizumi, N., Irisa, M., Maruno, T., Shimada, M., Shintani, K., Nishiumi, H.,
981 Yogo, R., Yanaka, S., Higo, D., *et al.* (2022). The Fab portion of immunoglobulin G has sites in the
982 CL domain that interact with Fc gamma receptor IIIa. *MAbs* *14*, 2038531.

983 Yamin, R., Jones, A.T., Hoffmann, H.H., Schafer, A., Kao, K.S., Francis, R.L., Sheahan, T.P., Baric,
984 R.S., Rice, C.M., Ravetch, J.V., *et al.* (2021). Fc-engineered antibody therapeutics with improved
985 anti-SARS-CoV-2 efficacy. *Nature* *599*, 465-470.

986




Figure 1: BNT162b2 induced IgG mediates age-dependent neutralization of wildtype and SARS-CoV-2 clinical variants. (A) Live SARS-CoV-2 neutralization (FRNT50) wildtype WA1 and receptor binding domain (RBD) specific IgG/M/A, IgG and IgA EC50 values (Supplemental Figure 1A) are plotted with relationship assessed by linear regression. (B) Neutralization of live SARS-CoV-2 wildtype WA1 and variants (Supplemental Figure 1B) are depicted with each dotted line representing a single individual and statistical significance calculated by Wilcoxon matched pair signed rank test. Live SARS-CoV-2 neutralization (FRNT50) for (C) wildtype (WT) and variants (D) B.1.1.7 (Alpha), (E) B.1.351 (Beta), (F) P.1 (Gamma), (G) B.1.617.2 (Delta) and (H) BA.2 (Omicron) and age in years are plotted with relationship assessed by linear regression and p values adjusted for sex.




Figure 2: Vaccine specific IgG induction of FcγRIIIa/CD16 effector functions correlate with neutralization of wildtype and SARS-CoV-2 clinical variants. Relationships between live SARS-CoV-2 WA1 neutralization (FRNT50) and receptor binding domain (RBD) specific relative binding to (A) FcγRIIIa/CD16a, (B) FcγRIIIa/CD32a and (C) FcγRIIb/CD32b, RBD specific antibody dependent natural killer cell activation (ADNKA) determined by (D) CD107a expression, (E) IFN γ production and (F) TNF α secretion, and (G) RBD specific antibody dependent neutrophil phagocytosis (ADNP) are shown. (H) Heatmap summarizes Spearman correlations (Supplemental Figure 2) between neutralization of SARS-CoV-2 wildtype WA1 and variants with relative binding of RBD specific IgG to activating (FcγRIIIa/CD16a and FcγRIIIa/CD32a), inhibitory (FcγRIIb/CD32b) and ratios of activating:inhibitory FcγR (FcγRIIIa/CD16a:FcγRIIb/CD32b and FcγRIIIa/CD32a:FcγRIIb/CD32b) binding and Fc effector functions ADNKA, antibody dependent cellular phagocytosis (ADCP), ADNP and antibody dependent complement deposition (ADCD). * $p \leq 0.05$; ** $p \leq 0.01$; *** $p \leq 0.001$; **** $p \leq 0.0001$.




Figure 3: Differential fucose and sialic acid on vaccine specific IgG link to FcγRIIIa/CD16a effector functions. Stacked column graphs depict the relative abundance of individual glycoforms (Supplemental Figure 3A-B) with respect to (A) total bulk non-antigen specific and (B) receptor binding domain (RBD) specific IgG. Each column represents one individual study participant. Dot plots summarize differences between bulk non-antigen specific and RBD specific IgG in the collective relative abundance of all individual glycoforms (Supplemental Figure 3C and D) containing (C) fucose, (D) total sialic acid, (E) di-sialic acid, (F) mono-sialic acid and (G) di-galactose with statistical significance calculated by Wilcoxon matched-pairs signed rank test. Data for (H) asialylated fucosylated, (I) total sialic and (J) total di-sialic acid, the three RBD specific glycoforms that have a statistically significant relationship across all markers of ADNKA activation, are plotted with CD107a expression per RBD specific IgG, as well as IFNγ and TNFα (Supplemental Figure 4). For comparison, data for (K) total mono-sialic acid is plotted.




Figure 4: Age influences some but not all vaccine specific antibody Fc γ R functions. The relationships between relative binding of receptor binding domain (RBD) specific IgG to (A) Fc γ RIIIa/CD16a, (B) Fc γ RIIa/CD32a and (C) inhibitory Fc γ RIIb/CD32b and age are shown. (D) Heatmap of the coefficient of determination (r^2) summarizes the goodness of fit across RBD and control respiratory syncytial virus (RSV), influenza (Flu) and anthrax antigens in Fc γ R binding and age. * $p \leq 0.05$; ** $p \leq 0.01$; *** $p \leq 0.001$; N/A not available given absence of significant detectable levels. The relationship between age and RBD antibody dependent natural killer cell activation (ADNKA) as measured by (E) CD107a and (F) TNF α , and (G) RBD antibody dependent cellular phagocytosis (ADCP) and (H) RBD antibody dependent neutrophil phagocytosis (ADNP) are shown. Linear regression with p values adjusted for sex are reported. (I) Radar plots depict vaccine specific IgG glycoforms calculated from the Z scored data for each individual RBD specific IgG glycoforms relative to bulk non-antigen specific IgG glycoforms with lines representing the median for each age group.









Figure 5: Enhanced BNT162b2 induced polyfunctional antibody breadth and magnitude against SARS-CoV-2 in younger compared to older adults. For each individual, the neutralization breadth across variants (Supplemental Figure 6A) and cumulative vaccine specific Fc functional magnitude from the sum of the Z scores for each of the individual effector functions (Supplemental Figure 6B) were calculated. (A) Grouped by neutralization breadth (top), each column shows the cumulative Fc functional score for one individual. Median, minimum and maximum ages characterizing each neutralization breadth group are shown (bottom). Polyfunctional antibody breadth was calculated for each individual (Supplemental Figure 6C) and used to categorize individuals into high (90-100%), medium (80-90%) or low (<80%) responders. The proportions of high, median and low responders are grouped by (B) age and (C) sex. (D) Radar plots depict vaccine specific polyfunctional antibody magnitude calculated from the Z scored data for each antibody function (Supplemental Figure 6C) with lines representing the median for each age group. (E) Heatmap summarizes Spearman correlations (Supplemental Figure 2) between neutralization of SARS-CoV-2 wildtype WA1 and variants with RBD specific IgG/M/A, IgG and IgA levels, relative binding of RBD specific IgG to activating (FcγRIIIa/CD16a and FcγRIIa/CD32a), inhibitory (FcγRIIb/CD32b) and ratios of activating:inhibitory FcγR (FcγRIIIa/CD16a:FcγRIIb/CD32b and FcγRIIa/CD32a:FcγRIIb/CD32b) binding and Fc effector functions antibody dependent natural killer cell activation (ADNKA), antibody dependent cellular phagocytosis (ADCP), antibody dependent neutrophil phagocytosis (ADNP) and antibody dependent complement deposition (ADCD) for each age group. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001.

BNT162b2-vaccinated donors	
Characteristic	Total (N=51)
Median age	50 yo (21-82)
Sex – no. (%)	
Female	28 (54.9%)
Male	23 (45.1%)
Median time between vaccine doses	21 days (20-22)
Median time between second dose and sample collection	14 days (14-15)


Table: Demographics and vaccination status




D

	WA1 (wildtype) FRNT50	B.1.1.7 (Alpha) FRNT50	B.1.351 (Beta) FRNT50	P.1 (Gamma) FRNT50	B.1.617.2 (Delta) FRNT50	BA.2 (Omicron) FRNT50
Spearman r	-0.6411	-0.6858	-0.5416	-0.4234	-0.5227	-0.6119
p	<0.0001	<0.0001	<0.0001	0.0022	<0.0001	<0.0001


Supplemental Figure 1: BNT162b2 vaccination induces IgG mediated neutralization of SARS-CoV-2 wildtype (WT) and clinical variants that diminish with age but are not altered by sex. (A) EC50 values are depicted for each individual for Nucleocapsid (N) specific antibodies, receptor binding domain (RBD) specific antibodies, IgG and IgA. Each column represents one individual. (B) Neutralization graphs from focus forming assays to calculate FRNT50 for each SARS-CoV-2 WT and clinical variants are shown. Each graph shows the data for one individual. (C) Dot plots show the distribution of neutralization for SARS-CoV-2 WT and variants by sex with statistical significance calculated by Mann-U-Whitney. (D) Spearman correlation coefficients and statistical significance between age and neutralization for SARS-CoV-2 WT and clinical variants are shown.




Supplemental Figure 2: Vaccine specific IgG induction of FcγRIIIa/CD16 effector functions correlate with neutralization of SARS-CoV-2 variants. (A) The relationships between live SARS-CoV-2 WA1 wildtype neutralization and RBD specific antibody dependent cellular phagocytosis (ADCP), and RBD specific antibody dependent complement deposition (ADCD), and receptor binding domain (RBD) specific relative binding ratios of activating:inhibitory FcγR FcγRIIIa/CD16a:FcγRIIb/CD32b, FcγRIIa/CD32a:FcγRIIb/CD32b are shown. (B) The relationships between live SARS-CoV-2 variants neutralization and RBD specific FcγRIIIa/CD16a binding and effector function antibody dependent natural killer cell activation (ADNKA) are depicted. Statistical significances were determined by Spearman correlation.




Supplemental Figure 3: Bulk total non-antigen and vaccine specific IgG glycosylation patterns diverge. (A) Human IgG1 contains a conserved Fc domain N297 residue on which a bi-antennary structure of N-acetylglucosamine (GlcNAc) and mannose resides. The subsequent addition and subtraction of galactose (G), fucose (F), N-acetylneuraminic acid (sialic acid) (S) and bisecting GlcNAc (B) contributes to post translational diversity that develops with antibody maturation through the Golgi and ER. (B) Capillary electrophoresis chromatographs for bulk total non-antigen and receptor binding domain (RBD) specific IgG glycans captured from one individual are shown. Quantification of each peak determines the relative abundance of each glycoform depicted. (C) The collective relative abundance of all individual glycoforms with fucose (F), sialic acid (S), galactose (G) and bisecting GlcNAc (B) are calculated for bulk total non-antigen and RBD specific IgG. Differences between bulk total non-antigen and RBD specific (D) agalactosylated and mono-galactosylated and (E) bisecting GlcNAc structures are shown. Statistical significances were calculated by Wilcoxon matched-pairs signed rank test.



Supplemental Figure 4: Differential fucose and sialic acid on vaccine specific IgG link Fc γ RIIIa/CD16a mediated IFN γ and TNF α production. Volcano plots depict slope and statistical significance (-log p) from linear regression assessing the dependency of receptor binding domain (RBD) ADNKA by (A) % CD56 CD107a, (B) IFN γ and (C) TNF α on different RBD specific IgG glycans. (D) Relationships where $p < 0.05$ are enumerated and identified. Data for antibody dependent natural killer cell activation (ADNKA) markers of IFN γ (middle row) and TNF α (bottom row) per RBD IgG and relative abundance of RBD specific (E and H) asialylated fucosylated, (F and I) total sialic and (G and J) total di-sialic acid are plotted. Statistical significances were evaluated by linear regression.



Supplemental Figure 5: Minimal relationship between age and vaccine specific antibody dependent complement deposition (ADCD). Receptor binding domain (RBD) specific C3 deposition and age are plotted (right panel). The relationship between age and RBD antibody dependent natural killer cell activation (ADNKA) as measured by IFN γ are shown (left panel). Linear regression with p value adjusted for sex is reported.



Supplemental Figure 6: Antibodies function by the combination of Fab and Fc domains. (A) Neutralization breadth across all 6 SARS-CoV-2 wildtype and clinical variants was calculated for each individual. In this cohort, individual responses fell into four main categories: those with detectable neutralizing activity for 100% of viruses tested, 83%, 67% and 50%. (B) Histograms depict the Z scored data for each vaccine specific Fc effector function tested. Each column represents one individual. Groupings are by neutralization breadth categories described in (A). (C) Vaccine specific polyfunctional breadth was calculated for each individual with all 20 vaccine specific features listed. In this cohort, individual responses fell into three main categories: those with high (90-100%), medium (80-90%) and low (<80%) of functions detected.